BRAIDED SCAFFOLDS

• US 20150081000A1
• Filed: 09/12/2014
• Published: 03/19/2015
• Est. Priority Date: 09/13/2013
• Status: Active Grant

• Current Assignee: Abbott Cardiovascular Systems Incorporated (Abbott Laboratories)
• Original Assignee: Abbott Cardiovascular Systems Incorporated (Abbott Laboratories)
• Inventors: Hossainy, Syed Faiyaz Ahmed, Papp, John E., Harrington, Joel
• Granted Patent: US 10,004,834 B2
• Time in Patent Office: Days
• US Class Current: 623/1.2
• CPC Class Codes: A61F 2/88 the wire-like elements formed as helical or spiral coils forming a net-like or mesh-like structure A61F2/90
• CPC Class Codes: A61F 2/90 characterised by a net-like or mesh-like structure
• CPC Class Codes: A61F 2/9517 handle assemblies therefor
• CPC Class Codes: A61F 2/966 with relative longitudinal movement between outer sleeve and prosthesis, e.g. using a push rod
• CPC Class Codes: A61F 2002/826 more than one stent being applied sequentially
• CPC Class Codes: A61F 2250/0018 differing in elasticity, stiffness or compressibility
• CPC Class Codes: A61F 2250/0031 made from both resorbable and non-resorbable prosthetic parts, e.g. adjacent parts
• CPC Class Codes: A61F 2250/0039 differing in diameter
• CPC Class Codes: A61F 2250/0067 Means for introducing or releasing pharmaceutical products into the body
• CPC Class Codes: A61L 31/128 containing other specific inorganic fillers not covered by A61L31/126 or A61L31/127
• CPC Class Codes: A61L 31/148 Materials at least partially resorbable by the body
• CPC Class Codes: C08L 67/04 Polyesters derived from hydroxycarboxylic acids, e.g. lactones C08L67/06 takes precedence

Abstract

A braided polymeric scaffold, made at least in part from a bioresorbable material is deployed on a catheter that uses a push-pull mechanism to deploy the scaffold. A drug coating is disposed on the scaffold. A plurality of scaffold segments on a catheter is also disclosed.

Claims

1. A self-expanding stent for treating a peripheral vessel comprising:

a braided scaffold comprising non-degradable filaments and degradable filaments woven to form a tubular configuration,

wherein the scaffold is self-expandable from a collapsed state to a deployed state,

wherein upon deployment to the deployed state, the biodegradable filaments degrade and a radial strength or stiffness of the scaffold decreases with time after deployment, and

wherein when the biodegradable filaments are completely degraded, the scaffold has a residual stiffness provided by the non-degradable filaments.

2. The stent of claim 1, wherein the non-degradable filaments are nitinol.

3. The stent of claim 1, wherein the degradable filaments comprise a polymer selected from the group consisting of poly(L-lactide), poly(L-lactide-co-glycolide), poly(DL-lactide), and polyglycolide.

4. The stent of claim 1, wherein the bioabsorbable filaments comprise a bioabsorbable polymer.

5. The stent of claim 1, wherein a radial strength or stiffness of the scaffold decreases by no greater than 60% during the first 3 months after deployment.

6. The stent of claim 1, wherein a radial strength or stiffness of the scaffold decreases by at least about 50% during the first 3 months after deployment.

7. The stent of claim 1, wherein a stiffness of the scaffold decreases to 40 to 60% of a stiffness at deployment during the first 3 months after deployment.

8. The stent of claim 1, wherein stiffness of the scaffold decreases to the residual stiffness which is less 40% to 60% of the deployed stiffness by at least 3 months after deployment.

9. The stent of claim 1, wherein the stiffness or radial strength of the scaffold varies along an axial length of the scaffold.

10. The stent of claim 9, wherein the residual stiffness is axially uniform and the stiffness at deployment varies axially.

11. The stent of claim 9, wherein at deployment the scaffold has a higher initial stiffness at proximal and distal ends of the scaffold which decreases to the residual stiffness when the polymer filaments are completely degraded.

12. The stent of claim 9, wherein at deployment proximal and distal end sections of the scaffold have a lower stiffness than a middle section, wherein the stiffness at the ends decreases faster to the residual stiffness than the middle section which reduces compliance mismatch between the scaffold and the vessel at the proximal and distal end sections.

13. A self-expanding stent for treating a peripheral vessel comprising:

a segmented braided scaffold including a plurality of braided scaffold segments configured to be deployed end to end in a vessel,

at least two of the braided scaffold segments are hybrid segments comprising non-degradable filaments and degradable filaments woven to form a tubular configuration,

wherein upon deployment from a collapsed state to a deployed state, the degradable filaments degrade and a radial strength or stiffness of the hybrid scaffold segments decreases with time after deployment, and

wherein when the biodegradable filaments are completely degraded, each hybrid segment comprises a residual stiffness provided by the non-degradable filaments.

14. The stent of claim 13, wherein selected hybrid segments have a higher radial strength or stiffness at deployment than other segments while having the same or different residual stiffness as the other segments.

15. The stent of claim 13, wherein a hybrid proximal end segment and a hybrid distal end segment of the scaffold have a higher radial strength or stiffness at deployment than middle segments while having the same or different residual radial strength or stiffness as the middle segments.

16. The stent of claim 13, wherein selected hybrid segments have a lower radial strength or stiffness at deployment than other segments while having the same or different residual radial strength or stiffness than the other segments.

17. The stent of claim 13, wherein a hybrid proximal end segment and a hybrid distal end segment have a lower radial strength or stiffness at deployment than middle segments while having the same or different residual stiffness than the other segments.

18. The stent of claim 13, wherein polymer filaments of selected hybrid segments have a higher degradation than other segments so that a rate a decrease to the residual stiffness is faster than other segments.

19. The stent of claim 13, wherein degradable filaments of a hybrid proximal end segment and a distal end segment have a higher degradation rate than hybrid middle segments so that a decrease in the residual stiffness is faster than in hybrid middle segments.

20. The stent of claim 13, wherein the degradable filaments comprise a polymer selected from the group consisting of poly(L-lactide), poly(L-lactide-co-glycolide), poly(DL-lactide), and polyglycolide.